Inicio › Mieloma múltiple › Distrito de Columbia › Washington
Ensayos clínicos de Mieloma múltiple en Washington, DC
22 estudios para Mieloma múltiple buscan participantes en centros de Washington y alrededores (a unos 30 millas). Abra un estudio para ver quién puede participar y cómo contactar con el equipo.
Texto oficial del estudio (inglés)
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
ReclutandoFase 1
- National Institutes of Health Clinical Center, Bethesda · A 7 mi de distancia
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
ReclutandoFase 3
- Research Site, Washington D.C.
Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
ReclutandoEstudio observacional
- National Institutes of Health Clinical Center, Bethesda · A 7 mi de distancia
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
ReclutandoFase 2
- National Institutes of Health Clinical Center, Bethesda · A 7 mi de distancia
Tissue Collection for Studies of Lymph Cancer
ReclutandoEstudio observacional
- National Institutes of Health Clinical Center, Bethesda · A 7 mi de distancia
Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)
ReclutandoFase 4
- American Oncology Partners, PA dba The Center for Cancer and Blood Disorders, Bethesda · A 7 mi de distancia
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
ReclutandoFase 3
- Center for Cancer and Blood Disorders, Bethesda · A 7 mi de distancia
18F-Fluciclovine PET/CT in Multiple Myeloma
ReclutandoFase 2
- National Institutes of Health Clinical Center, Bethesda · A 7 mi de distancia
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
ReclutandoFase 3
- American Oncology Partners, PA dba The Center for Cancer and Blood Disorders, Bethesda · A 7 mi de distancia
A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma
ReclutandoFase 2
- Lombardi Comprehensive Cancer Center, Washington D.C.
Collection of Tissue Samples for Cancer Research
ReclutandoEstudio observacional
- National Institutes of Health Clinical Center, Bethesda · A 7 mi de distancia
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
ReclutandoFase 3
- Georgetown University Medical Center, Washington D.C.
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
ReclutandoFase 3
- MedStar Washington Hospital Center MedStar Georgetown Cancer Institute, Washington D.C.
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
ReclutandoFase 2
- GSK Investigational Site, Bethesda · A 7 mi de distancia
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
ReclutandoFase 3
- Sibley Memorial Hospital, Washington D.C.
Mosaic Trial for Stem Cell Transplant Recipients
Reclutando
- Georgetown University School of Medicine, Washington D.C.
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
ReclutandoFase 1
- Maryland Oncology Hematology - Silver Spring /ID# 268562, Silver Spring · A 7 mi de distancia
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
ReclutandoFase 1/2
- The Center for Cancer and Blood Disorders (CCBD), Bethesda · A 7 mi de distancia
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
ReclutandoFase 3
- Sibley Memorial Hospital, Washington D.C.
Cancer Experience Registry (CER) for Cancer Patients and Caregivers
ReclutandoEstudio observacionalSe aceptan voluntarios sanos
- Cancer Support Community Research & Training Institute, Washington D.C.
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
ReclutandoFase 3
- GSK Investigational Site, Washington D.C.
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
ReclutandoFase 1/2
- Georgetown Lombardi Comprehensive Cancer Center, Washington D.C.
Más información sobre Mieloma múltiple en MedlinePlus
Ensayos de Mieloma múltiple en otras ciudades
- New York City, NY60 estudios
- Boston, MA42 estudios
- Atlanta, GA42 estudios
- Houston, TX38 estudios
- Durham, NC37 estudios
- Nashville, TN32 estudios
- Denver, CO27 estudios
- Rochester, MN24 estudios
- St. Louis, MO24 estudios
- Columbus, OH24 estudios
- Baldwin Park, CA23 estudios
- Chicago, IL22 estudios
Otros estudios en Washington
- Cáncer (todos los tipos)58 estudios
- Cáncer de pulmón de células no pequeñas55 estudios
- Cáncer de seno46 estudios
- Cáncer metastásico43 estudios
- Cáncer de pulmón41 estudios
- Cáncer de próstata38 estudios
- Obesidad33 estudios
- Cáncer del colon y del recto29 estudios
- Enfermedad cardiovascular28 estudios
- Cáncer de vejiga26 estudios
- Leucemia mielógena aguda24 estudios
- Cáncer de ovario23 estudios
De ClinicalTrials.gov, datos obtenidos el 6 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.